KOSPIBiotech & Pharma069620

Daewoong Pharma

₩98,600▼ 1.50%2026-11-18 close
Market Cap
₩1.1T
Turnover
₩2.2B
Volume
20K
Shares out.
11.6M
PER
6.4×
PBR
1.1×
EPS
₩15,951
Dividend Yield
0.59%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩600 per share · Prices as of the 2026-11-18 close

01

Report overview

Nabota exports drive profit; channel restructuring is the swing factor

Operating profit rose for three straight years to KRW 196.8 billion in 2025, then fell to a low of KRW 22.2 billion in the first quarter of 2026 before recovering in the second and third quarters, a rebound that leans on Nabota exports and temporary channel effects.

  1. 1

    2025 revenue reached KRW 1.57 trillion, up 10.4% from the prior year, and operating profit rose 33.0% to KRW 196.8 billion, lifting the operating margin to 12.5%.

  2. 2

    Operating profit bottomed at KRW 22.2 billion in the first quarter of 2026, down 48.8% from the prior quarter, and then rose to KRW 68.1 billion and KRW 71.3 billion in the second and third quarters.

  3. 3

    Nabota export revenue reached KRW 106.8 billion in the third quarter of 2026, up 127.9% year on year, according to preliminary separate-basis figures the company announced on November 4, 2026; the company said this included a temporary concentration of US shipments.

  4. 4

    Fexuclue sales fell 84.5% year on year in the third quarter as the product shifted to direct sales after the co-promotion ended, and the risk of drug price cuts in the second half of 2026 is also cited as a variable.

  5. 5

    Digital healthcare revenue was KRW 32.7 billion in the first half of 2026, far below the KRW 300 billion annual target the company set for its related business.

02

Business structure

Daewoong Pharma is centered on prescription drugs (ETC) and combines existing products, including the botulinum toxin Nabota, the acid-reflux drug Fexuclue and the over-the-counter liver product Urso, with a digital healthcare business.

The company said Nabota's sales grew an average of 57% a year after the US FDA approval in 2019, and cumulative Nabota sales passed KRW 1 trillion in June 2026. Third-quarter 2026 Nabota export revenue was KRW 106.8 billion, up 127.9% year on year (preliminary, separate basis, announced November 4, 2026).

Fexuclue is moving to direct sales after its co-promotion with Chong Kun Dang ended on August 31, 2026. Over-the-counter and digital healthcare revenue grew 21% and 40% year on year in the same quarter.

Digital healthcare centers on distribution of the thynC AI ward-monitoring system and medical devices, with revenue rising from KRW 50.9 billion in 2025 to KRW 32.7 billion in the first half of 2026, according to Huffpost Korea.

In February 2026 the company set a target of KRW 300 billion in annual revenue from the related business, while brokers expect about KRW 100 billion this year.

R&D rests on the affiliate Hanall Biopharma's barticlimab (HL161) program in immune-inflammatory disease and an epigenetic reprogramming (ERA) platform secured in May 2026. Most of the earnings still come from established products such as Nabota, Fexuclue and Urso.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩411.8B₩56.9B13.8%
2025Q4₩397.1B₩43.3B10.9%
2026Q1₩377.8B₩22.2B5.9%
2026Q2₩448.5B₩68.1B15.2%
2026Q3₩459.4B₩71.3B15.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.3T₩95.8B₩42.2B7.5%6.9%110.9%
2023₩1.4T₩122.6B₩121.7B8.9%15.9%94.1%
2024₩1.4T₩147.9B₩24.7B10.4%3.1%113.3%
2025₩1.6T₩196.8B₩195.9B12.5%19.5%108.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the disclosed annual figures, 2025 revenue was KRW 1.57 trillion, up 10.4% from the prior year, and the largest year in the 2022-2025 period. Operating profit rose from KRW 95.8 billion in 2022 to KRW 196.8 billion in 2025, increasing for three consecutive years from 2023 through 2025.

The operating margin climbed every year, from 7.5% in 2022 to 8.9% in 2023, 10.4% in 2024 and 12.5% in 2025, so profitability improved faster than revenue.

Net profit attributable to controlling shareholders rose 188.2% to KRW 121.7 billion in 2023, fell 79.7% to KRW 24.7 billion in 2024, the smallest year of the period, and then rose 691.8% to KRW 195.9 billion in 2025.

Net profit including non-controlling interests was KRW 192.9 billion in 2025, a different figure from profit attributable to controlling shareholders, so the two should be read separately.

Operating cash flow was KRW 118.2 billion in 2022, KRW 136 billion in 2023, KRW 51.5 billion in 2024 and KRW 149.2 billion in 2025, lowest in 2024. The debt-to-equity ratio was 110.9% in 2022, 94.1% in 2023, 113.3% in 2024 and 108.2% in 2025.

Quarterly operating profit fell from KRW 56.9 billion in the third quarter of 2025 to KRW 43.3 billion in the fourth quarter, down 23.8% quarter on quarter, and bottomed at KRW 22.2 billion in the first quarter of 2026, down 48.8%.

It then recovered to KRW 68.1 billion in the second quarter, up 206.5%, and KRW 71.3 billion in the third quarter, up 4.8% quarter on quarter and 25.4% year on year.

Brokers attributed the first-quarter drop to slower ETC sales growth and the channel restructuring toward block-type regional distribution hubs, while one analysis pointed to inventory adjustments, returns and fee settlements as temporary drags.

The company credited the third-quarter recovery to Nabota exports and growth in over-the-counter and digital healthcare, and the export figure included a temporary concentration of US shipments.

Net profit attributable to controlling shareholders was KRW 89.8 billion in the fourth quarter of 2025, KRW 25.9 billion in the first quarter of 2026, KRW 33.4 billion in the second quarter and KRW 34.4 billion in the third quarter, totaling KRW 183.5 billion over the last four quarters.

05

Industry analysis

The Korean pharmaceutical sector faces two pressures: drug price cuts and changes in distribution.

Analysts at Kiwoom Securities and Kyobo Securities wrote in a May 2026 report that after drug price cuts in 2025, the 2026 restructuring of distribution channels makes strong growth in the core pharma business hard to achieve. The same analysis flagged the risk of further drug price cuts from the second half of 2026.

Daewoong is reorganizing its distribution into block-type regional hubs, and the Korean Pharmacists' Association has demanded that the approach be halted, citing supply disruption and possible expansion of generic substitution.

The P-CAB class that includes Fexuclue is displacing the PPI-centered market; a November 2025 Samsung Securities report estimated P-CAB penetration rose from the low 20% range in 2024 to about 31% in the first half of 2025.

In botulinum toxin, Nabota's US exports are expanding, and the company is using bundled sales with filler products to strengthen its value positioning. A domestic civil appeal over a Nabota strain-related dispute has been flagged as a variable.

Compared with ETC-focused listed drugmakers, Daewoong has botulinum exports and digital healthcare as additional pillars, so changes in distribution and regulation touch several businesses at once.

06

Outlook

The near-term milestones the company has stated relate to Fexuclue. Fexuclue 10 mg and 40 mg will be sold solely by Daewoong from December 1, 2026, and the switch to direct sales for all doses is to be completed within 2026.

The company expects Fexuclue sales to recover in the fourth quarter as existing distribution inventory is used up. Brokers have argued that a fourth-quarter gap in US Nabota shipments will overlap with the Fexuclue transition.

The company said Nabota's position in the US market keeps expanding and new country entries continue, and it views medium-term growth potential positively.

On technology, on November 9, 2026 the company announced a joint development framework with two affiliates for high-concentration subcutaneous injection and dissolving microneedle platforms, targeting completion of dedicated manufacturing facilities in Seongnam and Hyangnam in 2027.

At a February 2026 vision event, the company said it would expand thynC supply to more than 100,000 beds and reach KRW 300 billion in annual revenue from the related business. Using the ERA platform secured in May 2026, the company has started work on an anti-aging therapy.

In May 2026 market observers expected a gradual normalization from the second half of 2026 as inventory adjustments end. The 2026 annual report, the next regular filing, will show whether Fexuclue sales recovered in the fourth quarter and how large the Nabota shipment gap was.

07

Valuation

PER
6.4×
PBR
1.1×
ROE
18.8%
EPS
₩15,951
BPS
₩93,076
Dividend per share
₩600

Valuation multiples are highly sensitive to earnings levels. Profit attributable to controlling shareholders rose from KRW 24.7 billion in 2024 to KRW 195.9 billion in 2025, then fell to KRW 25.9 billion in the first quarter of 2026.

It rose to KRW 33.4 billion in the second quarter and KRW 34.4 billion in the third, two consecutive quarterly increases, and totaled KRW 183.5 billion over the last four quarters.

The fourth quarter of 2025, at KRW 89.8 billion, sits inside that four-quarter total, so multiples read on a four-quarter basis change once that quarter drops out.

The price-to-book ratio should be read against controlling shareholders' equity of KRW 1.01 trillion at the end of 2025, and the question is where the market value sits relative to that base. The dividend yield is the annual dividend divided by the share price, so it moves with the share price.

The direction of recovery since the 2024 low is the starting point for interpreting the multiples, and because quarterly profit swings are large, the four-quarter and full-year bases should be read together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Nabota's export growth path

The company said Nabota's sales grew an average of 57% a year after the 2019 FDA approval, and cumulative sales passed KRW 1 trillion in June 2026. Third-quarter 2026 export revenue of KRW 106.8 billion was up 127.9%, which the company described as a record.

The company said a larger share of high-margin products supports overall profitability. The figure includes a temporary concentration of US shipments, so later quarters will need to confirm the trend.

A margin that has moved up

The operating margin rose every year, from 7.5% in 2022 to 8.9% in 2023, 10.4% in 2024 and 12.5% in 2025, while operating profit grew from KRW 95.8 billion to KRW 196.8 billion. Third-quarter 2026 consolidated operating profit of KRW 71.3 billion was up 25.4% year on year, faster than the 11.6% revenue growth.

A rising share of high-margin botulinum toxin and digital healthcare products is cited as the driver. Whether this structure holds during distribution restructuring like that of the first quarter of 2026 is the point to confirm.

New platforms and digital healthcare expansion

In November 2026 the company set up a joint development framework with two affiliates for high-concentration subcutaneous injection and microneedle platforms, targeting dedicated plants in Seongnam and Hyangnam in 2027. It secured the ERA platform in May 2026.

In digital healthcare it targets more than 100,000 beds for thynC and KRW 300 billion in annual revenue. First-half 2026 revenue of KRW 32.7 billion is still far from that target, but the direction of widening the business toward a biotech platform is clear.

09

Bear factors

The first-quarter 2026 hit from channel restructuring

Analysts said first-quarter 2026 operating profit of KRW 22.2 billion fell 42.6% year on year. The market attributed this to slower ETC sales growth and the simplification of distribution through block-type regional hubs.

Analysts at Kiwoom Securities and Kyobo Securities said ETC volume fell as inventory was cleared during the channel reshuffle. Profit attributable to controlling shareholders dropped 71.2% quarter on quarter to KRW 25.9 billion.

The recovery since then is real, but how temporary the first-quarter low was will be clear only from results after the fourth quarter.

The temporary nature of Nabota shipments

The company's third-quarter announcement said the KRW 106.8 billion of Nabota export revenue included a temporary concentration of US shipments. Brokers expect a gap in US Nabota shipments in the fourth quarter.

When export revenue swings sharply, operating profit swings with it, so the KRW 71.3 billion third-quarter result may have been partly affected. Profit attributable to controlling shareholders fell 25.8% year on year to KRW 34.4 billion in the third quarter, which is another reason to examine the quality of earnings.

Fexuclue's direct-sales transition and price pressure

Fexuclue moved to direct sales after the co-promotion with Chong Kun Dang ended on August 31, 2026, and third-quarter Fexuclue sales fell 84.5% year on year. Over the same quarter ETC sales fell 3.1% to KRW 218.4 billion, according to Huffpost Korea.

After the 2025 drug price cuts, the risk of further cuts in the second half of 2026 has been raised, which could limit the pace of ETC revenue recovery. The company expects Fexuclue sales to recover during the fourth quarter.

10

Risk factors

Litigation and IP

A domestic civil appeal over a Nabota strain-related dispute was flagged as a risk in a November 2025 brokerage report, with a second-instance ruling possible during 2026. That report also noted an agreement that the global business is independent of the domestic outcome, which limits the practical impact. The effect on domestic sales and the brand is still open until a ruling is issued.

Distribution channels and inventory

The move to block-type regional distribution produced returns, fee settlements and inventory adjustments that temporarily weighed on profitability. The Korean Pharmacists' Association has demanded that block distribution be stopped and criticized possible supply disruption.

The Fexuclue transition also involves a period of clearing existing stock. If the restructuring takes longer than expected, the pace of margin recovery after the second half of 2026 could slow.

Financial and investment load

The debt-to-equity ratio was 110.9% in 2022, 94.1% in 2023, 113.3% in 2024 and 108.2% in 2025, staying at a high level. Total liabilities at the end of 2025 were KRW 1.23 trillion against total equity of KRW 1.13 trillion.

Large investments, including Nabota production capacity and a headquarters building, have been cited as drivers of higher debt. With platform expansion and digital healthcare investment running in parallel, whether operating cash flow covers that burden is the key question.

11

What to watch next

  1. December 1, 2026

    The date Daewoong begins selling Fexuclue 10 mg and 40 mg on its own. It is the checkpoint for whether the third-quarter drop in Fexuclue sales recovers under direct sales.

  2. By end of 2026

    The target for completing direct sales across all Fexuclue doses. Revenue volatility from the distribution change can only be judged once the transition is complete.

  3. By end of March 2027 (annual report filing deadline)

    The 2026 annual report, the next regular filing. It will show the fourth-quarter operating margin, whether Fexuclue recovered and the size of the US Nabota shipment gap.

  4. 2027

    The target year for completing dedicated plants in Seongnam and Hyangnam. It is the point to gauge how quickly the high-concentration injection and microneedle platforms move toward commercialization.

12

Overall view

On the disclosed figures, Daewoong's revenue and operating profit both rose from 2022 onward, and the operating margin climbed from 7.5% in 2022 to 12.5% in 2025.

Operating profit bottomed at KRW 22.2 billion in the first quarter of 2026 and then rose in the second and third quarters, but the third-quarter Nabota export gain includes a temporary US shipment effect. Brokers expect the fourth quarter to combine a gap in US Nabota shipments with the Fexuclue transition.

Bullish factors are overseas Nabota growth, a larger share of high-margin products and new platform technologies. Bearish factors are whether the distribution restructuring persists, volatility in Fexuclue sales and the risk of drug price cuts in the second half of 2026.

The gap between the KRW 300 billion digital healthcare target and KRW 32.7 billion of first-half 2026 revenue remains wide. The next checkpoints are the December 1, 2026 switch to direct sales of Fexuclue and the fourth-quarter operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. v.daum.net
  2. samsungpop.com
  3. view.asiae.co.kr
  4. kormedi.com
  5. huffingtonpost.kr
  6. kpanews.co.kr
  7. medipana.com
  8. biz.newdaily.co.kr
  9. news.bizwatch.co.kr
  10. press9.kr
  11. insight.co.kr
  12. vegannews.co.kr
  13. viva100.com
  14. huffingtonpost.kr
  15. medicaldaily.co.kr
  16. m.news.nate.com
  17. asiatime.co.kr
  18. shinailbo.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis